Background: patients’ quality of life and disease activity measurements in SLE are necessary for optimal patient care. They are central to clinical guidelines and treat-to-target approaches, which have been shown to improve outcomes in SLE, and rely on specifically defining and measuring low disease activity and remission. Disease exacerbations or flares in SLE span in range of severity from mild or moderate episodes that can be managed in the clinic to life threatening flares that require hospitalization. These flares place patients at risk for permanent organ damage, are associated with significant morbidity, and contribute to increased healthcare costs. Limiting the frequency and severity of flares has been an ongoing objective in SLE disease management, with extensive research focused on assessment of imminent flare risk and development of flare prediction biomarkers. SLE patients experience events related to disease activity, irreversible damage, and medications’ side effects which may negatively impact their HRQoL and eventually may result in disability (25%-57%). Thus, their evaluation should include disease activity, severity and HRQoL. HRQoL in SLE is lower than in the general population and in patients with other common chronic diseases and comparable to that of other severe medical illnesses, such as the acquired immunodeficiency syndrome (AIDS), Sjögren´s syndrome and rheumatoid arthritis; however, it is less impaired than in fibromyalgia.